|
|
|
|
|
Legal status
Patent not validated
| (51) | INT.CL. | A61K 39/395 | |
| A61K 38/16 | |||
| A61K 31/7088 | |||
| A61P 17/00 |
| (11) | Number of the document | 2475388 |
| (13) | Kind of document | T |
| (96) | European patent application number | 10815921.1 |
| Date of filing the European patent application | 2010-09-01 | |
| (97) | Date of publication of the European application | 2012-07-18 |
| (45) | Date of publication and mention of the grant of the patent | 2017-11-08 |
| (46) | Date of publication of the claims translation |
| (86) | Number | PCT/US2010/047461 |
| Date | 2010-09-01 |
| (87) | Number | WO 2011/031600 |
| Date | 2011-03-17 |
| (30) | Number | Date | Country code |
| 241324 P | 2009-09-10 | US |
| (72) |
RANKIN, Andrew, L., US
PFLANZ, Stefan, US
MUMM, John, US
|
| (73) |
Merck Sharp & Dohme Corp.,
126 East Lincoln Avenue, Rahway, NJ 07065-0907,
US
|
| (54) | USE OF IL-33 ANTAGONISTS TO TREAT FIBROTIC DISEASE |
| USE OF IL-33 ANTAGONISTS TO TREAT FIBROTIC DISEASE |